Functional interaction between SNPS and microsatellite in the transcriptional regulation of insulin-like growth factor 1

Human Mutation

Volumn 34, Issue 9, 2013, Pages 1289-1297

  Chen, Holly Y ^a   Huang, Wei ^b   Leung, Vincent H K ^a   Fung, Simon L M ^a   Ma, Suk Ling ^a   Jiang, Hongling ^c   Tang, Nelson L S ^a,d,e  

^a Prince of Wales Hospital   (Hong Kong)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e KIZ/CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases   (China)

Author keywords

Genetic interaction; IGF1; Promoter; SNP; Transcriptional activity

Indexed keywords

SOMATOMEDIN C;

ARTICLE; ENZYME ASSAY; GENE EXPRESSION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 84881609806     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22363     Document Type: Article

References (33)

1. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, et al. 2006. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1-10.
2. Chen HY, Chan IH, Sham AL, Leung VH, Ma SL, Ho SC, Tang NL. 2011. Haplotype effect in the IGF1 promoter accounts for the association between microsatellite and serum IGF1 concentration. Clin Endocrinol (Oxf) 74:520-527.
3. Clark RG. 2004. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations. Horm Res 62 Suppl 1:93-100.
4. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, Lombardi G, Savastano S. 2008. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 159:389-397.
5. Delellis K, Ingles S, Kolonel L, Mckean-Cowdin R, Henderson B, Stanczyk F, Probst-Hensch NM. 2003. IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 88:277-282.
6. Eleswarapu S, Ge X, Wang Y, Yu J, Jiang H. 2009. Growth hormone-activated STAT5 may indirectly stimulate IGF-I gene transcription through HNF-3{gamma}. Mol Endocrinol 23:2026-2037.
7. Fehringer G, Ozcelik H, Knight JA, Paterson AD, Boyd NF. 2009. Association between IGF1 CA microsatellites and mammographic density, anthropometric measures, and circulating IGF-I levels in premenopausal Caucasian women. Breast Cancer Res Treat 116:413-423.
8. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D. 2001. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926-1934.
9. Fintini D, Brufani C, Cappa M. 2009. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther Clin Risk Manag 5:553-559.
10. Frayling TM, Hattersley AT, Mccarthy A, Holly J, Mitchell SM, Gloyn AL, Owen K, Davies D, Smith GD, Ben-Shlomo Y. 2002. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 51:2313-2316.
11. Frazer KA, Pachter L, Poliakov A, Rubin EM, Dubchak I. 2004. VISTA: computational tools for comparative genomics. Nucleic Acids Res 32:W273-W279.
12. Hartley JL, Temple GF, Brasch MA. 2000. DNA cloning using in vitro site-specific recombination. Genome Res 10:1788-1795.
13. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34.
14. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, Sousa AM, Pletikos M, Meyer KA, Sedmak G, Guennel T, Shin Y, et al. 2011. Spatio-temporal transcriptome of the human brain. Nature 478:483-489.
15. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162.
16. Kunzler P, Matsuo K, Schaffner W. 1995. Pathological, physiological, and evolutionary aspects of short unstable DNA repeats in the human genome. Biol Chem Hoppe Seyler 376:201-211.
17. Laconi E. 2000. Differential growth: from carcinogenesis to liver repopulation. Am J Pathol 156:389-392.
18. Li L, Cicek MS, Casey G, Witte JS. 2004. No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 13:497-498.
19. Martin P, Makepeace K, Hill SA, Hood DW, Moxon ER. 2005. Microsatellite instability regulates transcription factor binding and gene expression. Proc Natl Acad Sci USA 102:3800-3804.
20. Mayer AK, Muehmer M, Mages J, Gueinzius K, Hess C, Heeg K, Bals R, Lang R, Dalpke AH. 2007. Differential recognition of TLR-dependent microbial ligands in human bronchial epithelial cells. J Immunol 178:3134-3142.
21. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. 2005a. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 14:1394-1401.
22. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. 2005b. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: personal and lifestyle factors (United States). Cancer Causes Control 16:917-927.
23. Olivier M. 2004. From SNPs to function: the effect of sequence variation on gene expression. Focus on "a survey of genetic and epigenetic variation affecting human gene expression". Physiol Genomics 16:182-183.
24. Palles C, Johnson N, Coupland B, Taylor C, Carvajal J, Holly J, Fentiman IS, Silva Idos S, Ashworth A, Peto J, Fletcher O. 2008. Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. Hum Mol Genet 17:1457-1464.
25. Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
26. Pollak MN, Schernhammer ES, Hankinson SE. 2004. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518.
27. Rockman MV, Wray GA. 2002. Abundant raw material for cis-regulatory evolution in humans. Mol Biol Evol 19:1991-2004.
28. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP. 1998. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83:2286-2290.
29. Schildkraut JM, Demark-Wahnefried W, Wenham RM, Grubber J, Jeffreys AS, Grambow SC, Marks JR, Moorman PG, Hoyo C, Ali S, Walther PJ. 2005. IGF1 (CA)19 repeat and IGFBP3-202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 14:403-408.
30. Shankar A, Li J. 2008. Positive association between high-sensitivity C-reactive protein level and diabetes mellitus among US non-Hispanic black adults. Exp Clin Endocrinol Diabetes 116:455-460.
31. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
32. Telgmann R, Dordelmann C, Brand E, Nicaud V, Hagedorn C, Pavenstadt H, Cambien F, Tiret L, Paul M, Brand-Herrmann SM. 2009. Molecular genetic analysis of a human insulin-like growth factor 1 promoter P1 variation. FASEB J 23:1303-1313.
33. Wardrop SL, Brown MA. 2005. Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene. Genomics 86:316-328.